Analyst Reco. ResMed, Inc.

Equities

RMD

US7611521078

Market Closed - Nyse Other stock markets 01:30:02 26/06/2024 am IST			5-day change	1st Jan Change
183.8 ^USD	+0.90%		-13.39%	+6.87%

25/06	Oppenheimer Downgrades ResMed to Market Perform From Outperform	MT
24/06	Shares of ResMed, Inspire Medical Down After Eli Lilly Provides Sleep Apnea Study Update	DJ

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Oppenheimer Downgrades ResMed to Market Perform From Outperform	25/06	MT
Shares of ResMed, Inspire Medical Down After Eli Lilly Provides Sleep Apnea Study Update	24/06	DJ
Resmed Insider Sold Shares Worth $3,107,739, According to a Recent SEC Filing	11/06	MT
Resmed Insider Sold Shares Worth $2,747,810, According to a Recent SEC Filing	11/05	MT
Resmed Insider Sold Shares Worth $3,178,815, According to a Recent SEC Filing	09/05	MT
KeyBanc Adjusts Price Target on ResMed to $238 From $227	26/04	MT
Jefferies Adjusts Price Target on ResMed to $180 From $164	26/04	MT
Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating	26/04	MT
JPMorgan Adjusts Price Target on ResMed to $225 From $198	26/04	MT
Mizuho Adjusts Price Target on ResMed to $220 From $215	26/04	MT
Needham Adjusts Price Target on ResMed to $236 From $224	26/04	MT
Morgan Stanley Adjusts Price Target on ResMed to $219 From $207	26/04	MT
RBC Adjusts Price Target on ResMed to $200 From $187	26/04	MT
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	01/04	MT
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	06/03	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	04/03	MT
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	05/02
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	30/01	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	30/01	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	25/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 04:25 pm IST